1/ Today is #BlackHoleFriday, an annual science outreach event that, by complete coincidence I’m sure, is done on #BlackFriday. You’ll read lots of cool stuff about black holes on the hashtag. Here’s mine.
https://t.co/QetnodyE72
#BlackHoleFriday
More from Science
#DDDD $LBPS $LOAC
A thread on the potential near term catalysts behind why I have increased my position in 4d Pharma @4dpharmaplc (LON: #DDDD):
1) NASDAQ listing. This is the most obvious.
The idea behind this is that the huge pool of capital and institutional interest in the NASDAQ will enable a higher per-share valuation for #DDDD than was achievable in the UK.
Comparators to @4dpharmaplc #DDDD (market capitalisation £150m) on the NASDAQ and their market capitalisation:
Seres Therapeutics: $2.33bn = £1.72bn (has had a successful phase 3 C. difficile trial); from my previous research (below) the chance of #DDDD achieving this at least once is at least
Kaleido Biosciences: $347m = £256m. 4 products under consideration, compared to #DDDD's potential 16. When you view @4dpharmaplc's 1000+ patents and AI-driven MicroRx platform (not to mention their end-to-end manufacturing capability), 4d's undervaluation is clear.
A thread on the potential near term catalysts behind why I have increased my position in 4d Pharma @4dpharmaplc (LON: #DDDD):
1) NASDAQ listing. This is the most obvious.
The idea behind this is that the huge pool of capital and institutional interest in the NASDAQ will enable a higher per-share valuation for #DDDD than was achievable in the UK.
Comparators to @4dpharmaplc #DDDD (market capitalisation £150m) on the NASDAQ and their market capitalisation:
Seres Therapeutics: $2.33bn = £1.72bn (has had a successful phase 3 C. difficile trial); from my previous research (below) the chance of #DDDD achieving this at least once is at least
While looking at speculative pharmaceutical stocks I am reminded of why I am averse to these risky picks.#DDDD was compelling enough, though, to break this rule. The 10+ treatments under trial, industry-leading IP portfolio, and comparable undervaluation are inescapable.
— Shrey Srivastava (@BlogShrey) December 16, 2020
Kaleido Biosciences: $347m = £256m. 4 products under consideration, compared to #DDDD's potential 16. When you view @4dpharmaplc's 1000+ patents and AI-driven MicroRx platform (not to mention their end-to-end manufacturing capability), 4d's undervaluation is clear.
I think we have to expand our thinking about the toroidal sphere even more. When looking at maps, I noticed the da Vinci map, from 1514, which uses the Reuleaux Triangle. This triangle is formed from 3 intersecting circles, and is in the center of a trefoil.
The trefoil is the focal point in many gothic structures, repeatedly and prominently shown. It is represented in many ways. ‘Going down the rabbit hole’ now makes sense, if you understand the center point of the ears is the center of the torus, with the rabbit trefoil.
The trefoil can be found within the toroidal field. Here is a fun site, where you can manipulate it yourself. https://t.co/FCMcybuuFC
The wiki page makes it seem like there isn’t much of importance with the Reuleaux Triangle, besides being used for coinage, or some stupid bike. But the Wankel engine is an interesting engine, using this geometric design https://t.co/ayPOgkAqGN
https://t.co/m9EaWwF796
The trefoil is the focal point in many gothic structures, repeatedly and prominently shown. It is represented in many ways. ‘Going down the rabbit hole’ now makes sense, if you understand the center point of the ears is the center of the torus, with the rabbit trefoil.
The trefoil can be found within the toroidal field. Here is a fun site, where you can manipulate it yourself. https://t.co/FCMcybuuFC
The wiki page makes it seem like there isn’t much of importance with the Reuleaux Triangle, besides being used for coinage, or some stupid bike. But the Wankel engine is an interesting engine, using this geometric design https://t.co/ayPOgkAqGN
https://t.co/m9EaWwF796